Stryker Corporation SYK

Stryker Corporation es una empresa de tecnología médica. La compañía ofrece una variedad de tecnologías médicas, incluyendo productos ortopédicos, médicos y quirúrgicos, así como neurotecnología y productos de columna. Sus segmentos incluyen Ortopedia, MedSurg, Neurotecnología y Columna. El segmento de Ortopedia incluye sistemas de implantes reconstructivos (cadera y rodilla) y de traumatología, entre otros productos relacionados. El segmento de MedSurg incluye equipos quirúrgicos y sistemas de navegación quirúrgica; sistemas endoscópicos y de comunicaciones; equipos médicos de manejo de pacientes, equipos médicos de emergencia, productos desechables de cuidados intensivos; dispositivos médicos reprocesados y remanufacturados, y otros productos relacionados. El segmento de Neurotecnología y Columna incluye productos neurovasculares, sistemas de implantes espinales y otros productos relacionados. Sus productos incluyen implantes que se utilizan en cirugías de reemplazo articular y traumatología, entre otros productos. Ofrece cuidado musculoesquelético y tecnología de sensores para reemplazo total de articulaciones.

Con 4 acciones de SYK (USD 1.132,45) habrías recibido USD 14,08 en dividendos en los últimos 12 meses.

SYK hizo una división de acciones (split) de 2:1 el 17 de mayo de 2004: cada acción se convirtió en 2. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 5 oct

  Spain General Hospital Supplies Market Report 2026: Revenue, Volume, Pricing and Competitive Analysis (2018-2033) | Hospital Beds, Exam Tables, Exam Room Stools, and More

  ResearchAndMarkets.com released a comprehensive market report on Spain's general hospital supplies sector, covering historical and forecast data from 2018 to 2033. The report analyzes market revenues, volumes, and pricing across key product segments including hospital beds, IV poles, exam tables, and surgical clippers, with 2025 competitive share data for major market players.

  

• Zacks Investment Research 2 oct

  GEHC vs. SYK: Which Stock Should Value Investors Buy Now?

  In a comparison of two medical products stocks, GE HealthCare Technologies (GEHC) emerges as the more attractive option for value investors compared to Stryker (SYK). GEHC has a higher Zacks Rank (#2 Buy vs #3 Hold), lower forward P/E ratio (12.97 vs 18.23), and a lower P/B ratio (2.63 vs 4.36), earning a Value grade of B compared to SYK's C grade.

  

• GlobeNewswire Inc. 25 sept

  ELFA Names James Cress Acting President & CEO

  The Equipment Leasing & Finance Association (ELFA) announced that James Cress, its Immediate Past Chair, will serve as Acting President & CEO while the board searches for a permanent replacement following Leigh Lytle's departure later in 2026. Cress brings over 30 years of banking and equipment finance experience, including 18 years at Stryker leading its captive finance business.

  

• GlobeNewswire Inc. 25 sept

  Canada General Hospital Supplies Market Report 2026: Delivers Revenue, Volume, Pricing and Competitive Insights Through 2033

  ResearchAndMarkets.com released a comprehensive market report on Canada's general hospital supplies sector covering 2018-2033. The report analyzes eight product segments including hospital beds, IV poles, exam tables, and surgical clippers, providing revenue, volume, and pricing data. It includes competitive positioning of key market players and identifies growth opportunities for manufacturers, suppliers, and investors in Canada's healthcare equipment market.

  

• Zacks Investment Research 23 sept

  Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?

  Intuitive Surgical and Stryker represent two distinct approaches to robotic-assisted surgery. ISRG demonstrates stronger operational momentum with 16% procedure growth and expanding digital ecosystem, earning a Zacks Rank #2 (Buy) rating. Stryker shows recovery potential with record Mako installations and diversified MedTech portfolio but receives a Zacks Rank #3 (Hold) rating. ISRG trades at a premium valuation (34.54X P/E) reflecting growth expectations, while SYK trades at a discount (16.95X P/E) providing valuation support.